Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Cheifetz

Showing results (11-20 of 263) with videos related to

Pageof 27
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 23, 2013
The holistic effects of cannabis in Crohn's diseaseConor Lahiff, Adam S Cheifetz
Digestive Diseases and Sciences|March 31, 2019
Integrin Calculus: The Predictive Power of Vedolizumab Concentrations in IBD TherapyKonstantinos Papamichael, Adam S Cheifetz
Current Opinion in Rheumatology|May 16, 2020
Therapeutic drug monitoring in patients on biologics: lessons from gastroenterologyKonstantinos Papamichael, Adam S Cheifetz
Inflammatory Bowel Diseases|July 22, 2015
Reply to Use of CT Scan in Ulcerative Colitis Patients Presenting to the Emergency DepartmentLaurie Gashin, Adam S Cheifetz
The Journal of Rheumatology|August 4, 2012
Infusion reactions related to infliximab therapy are not usually associated with drug discontinuationGarrett Cullen, Adam S Cheifetz
Expert Opinion on Drug Metabolism & Toxicology|January 8, 2022
Optimizing therapeutic drug monitoring in inflammatory bowel disease: a focus on therapeutic monoclonal antibodiesKonstantinos Papamichael, Adam S Cheifetz
Inflammatory Bowel Diseases|November 6, 2010
Infliximab decreases colectomy rates in moderate to severe ulcerative colitis: big news or big deal?Adam S Cheifetz, Laura Rosenberg
Alimentary Pharmacology & Therapeutics|April 4, 2017
Editorial: therapeutic de-escalation of anti-tumour necrosis factor therapy - is less enough?K Papamichael, A S Cheifetz
The American Journal of Gastroenterology|February 22, 2017
Therapeutic Drug Monitoring in IBD: The New Standard-of-Care for Anti-TNF TherapyKonstantinos Papamichael, Adam S Cheifetz
Alimentary Pharmacology & Therapeutics|April 18, 2013
Commentary: irritable bowel syndrome and the CDAI--misleading activity by straw men; authors' replyC Lahiff, A S Cheifetz
Pageof 27

Showing results (11-20 of 263) with videos related to

Sort By:
Pageof 27
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 23, 2013
The holistic effects of cannabis in Crohn's diseaseConor Lahiff, Adam S Cheifetz
Digestive Diseases and Sciences|March 31, 2019
Integrin Calculus: The Predictive Power of Vedolizumab Concentrations in IBD TherapyKonstantinos Papamichael, Adam S Cheifetz
Current Opinion in Rheumatology|May 16, 2020
Therapeutic drug monitoring in patients on biologics: lessons from gastroenterologyKonstantinos Papamichael, Adam S Cheifetz
Inflammatory Bowel Diseases|July 22, 2015
Reply to Use of CT Scan in Ulcerative Colitis Patients Presenting to the Emergency DepartmentLaurie Gashin, Adam S Cheifetz
The Journal of Rheumatology|August 4, 2012
Infusion reactions related to infliximab therapy are not usually associated with drug discontinuationGarrett Cullen, Adam S Cheifetz
Expert Opinion on Drug Metabolism & Toxicology|January 8, 2022
Optimizing therapeutic drug monitoring in inflammatory bowel disease: a focus on therapeutic monoclonal antibodiesKonstantinos Papamichael, Adam S Cheifetz
Inflammatory Bowel Diseases|November 6, 2010
Infliximab decreases colectomy rates in moderate to severe ulcerative colitis: big news or big deal?Adam S Cheifetz, Laura Rosenberg
Alimentary Pharmacology & Therapeutics|April 4, 2017
Editorial: therapeutic de-escalation of anti-tumour necrosis factor therapy - is less enough?K Papamichael, A S Cheifetz
The American Journal of Gastroenterology|February 22, 2017
Therapeutic Drug Monitoring in IBD: The New Standard-of-Care for Anti-TNF TherapyKonstantinos Papamichael, Adam S Cheifetz
Alimentary Pharmacology & Therapeutics|April 18, 2013
Commentary: irritable bowel syndrome and the CDAI--misleading activity by straw men; authors' replyC Lahiff, A S Cheifetz
Pageof 27